Pharmacokinetics and Distribution of Dapsone in Leucocytes After Single-dose and Multiple-dose Administration

Methemoglobinemia Clinical Trial

Official title: Pharmacokinetics and Distribution of Dapsone (DDS) in Leucocytes After Single-dose and Multiple-dose Administration in Healthy Subjects Genotyped for CYP2C9 and NAT2 and in Patients With Autoimmune Bullous Dermatoses

Status Completed

Clinical Trial Summary

The objectives of the study are

• to evaluate pharmacokinetics, distribution in blood leucocytes, metabolism and methemoglobinemia after single-dose and repeated-dose administration of 100 mg of dapsone in healthy subjects genotyped for CYP2C9 and NAT2

• to evaluate serum through levels, distribution in blood leucocytes and methemoglobinemia after repeated-dose treatment with dapsone in patients with autoimmune bullous dermatoses before and after concomitant treatment with glucocorticoids

Clinical Trial Description

Dapsone (diamino diphenyl sulphone, DDS) was synthesized by Emil Fromm and Jakob Wittmann in Freiburg (Germany) in 1908. In 1937, the anti-inflammatory potency of dapsone was discovered in experimentally-induced infections in mice. Since 1941, dapsone (as Promin®) is used with great success in the therapy of leprosy. Dapsone is a mainstay in the treatment of leprosy, being one of the components of the multidrug regimen advised by the World Health Organization (WHO).

In 1950, Esteves and Brandão confirmed the efficacy of the drug in patients with dermatitis herpetiformis Duhring. Sneddon and Wilkinson in England reported a remission as caused by dapsone in a patient with subcorneal pustulosis. The efficacy of dapsone in treatment of pemphigus vulgaris was initially reported by Winkelmann and Roth in 1960.

After oral administration, dapsone is almost completely absorbed from the gastrointestinal tract with bioavailability of more than 86 %. Maximum serum concentrations between 0,63 and 4,82 mg/l are attained within 2-8 hours after single doses between 50 mg and 300 mg. At steady-state, the serum concentration fluctuate between 3,26 mg/l and 1,95 mg/l chronic treatment with 100 mg dapsone once daily (s.i.d.).

Dapsone is distributed to all organs, it crosses the blood-brain barrier and placenta and is detected in breast milk.

About 20% of dapsone is excreted unchanged into the urine, 70-85% as water-soluble metabolites additionally to a small amount in feces.

Dapsone is nearly completely metabolized in the liver and in activated polymorphic neutrophils (PMN) and/or mononuclear cells. The major metabolic pathway in the liver is N-acetylation by the polymorphic N-acetyltransferase 2 (NAT2) and N-oxidation by cytochrome P-450 (CYP) enzymes. Major metabolites are monoacetyl-dapsone (MADDS) and dapsone hydroxylamine (DDS-NOH). Dapsone undergoes enterohepatic circulation.

MADDS is subjected also to significant deacetylation. A constant equilibrium between acetylation and deacetylation is reached within a few hours after the oral administration of either dapsone or MADDS. The acetylation ratio shows a large interindividual variation, ranging from 0.1 to 2.0. These ratios show a bimodal distribution pattern.

Acetylation is not the rate-determining step in overall elimination of dapsone. The amount of MADDS excreted in urine is very low because it is largely deacetylated to dapsone before excretion into the urine. Between slow acetylators (SA) and rapid acetylators (RA), there are no differences neither in dapsone serum concentrations nor any pharmacokinetic parameters of dapsone. Also, the therapeutic response is the same in both acetylator phenotypes.

However, excretion of both MADDS and its conjugated derivatives is higher in RA. Therefore, dapsone may be used for determination of the NAT2 phenotype even though these metabolites represent only a very small fraction of the dose.

MADDS is highly bound to plasma proteins (> 98%), about 20-25 times more tightly than dapsone. Presumably, the small fraction of unbound MADDS and its strong binding to plasma proteins are reasons for its low availability in erythrocytes (erythrocyte/plasma ratio = 0.33). Tight protein binding is also the reason behind low glomerular filtration rate of the metabolite; therefore the half-life for MADDS is approximately 20-25 hours, similar like for dapsone.

Microsomal N-hydoxylation is the second major metabolic route of dapsone which seems to be associated with hematological side effects of the drug. However, the data on excretion of free and conjugated DDS-NOH vary widely in the literature. No reliable information is available on excretion of hydroxylated MADDS compounds.

In terms of efficacy and safety of dapsone, most important is the generation of DDS-NOH, that also occurs in inflamed lesions of the skin as mediated by activated PMN. Thus, over the years, dapsone became a first-line drug in the treatment of dermatitis herpetiformis Duhring, Sneddon-Wilkinson-Syndrome and further bullous autoimmune dermatoses. Most recently was found, that formation of DDS-NOH is mainly under control of CYP2C9 in-vitro.(Lit.) Because of the known CYP2C9 gene polymorphisms (about 4-6 % are poor metabolizers, PM), efficacy of the drug in bullous autoimmune dermatoses may be dependent on the metabolizer status of the patients.

The investigators hypothesize, that subjects which are slow acetylators of NAT2 (SA) but extensive metabolizers of CYP2C9 (EM) may form significantly higher levels of the active metabolite DDS-NOH than rapid acetylators of NAT2 (RA) being PM of CYP2C9 (PM). ;

Study Design

Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science

Related Conditions & MeSH terms

• Linear IgA Bullous Dermatosis
• Methemoglobinemia
• Skin Diseases

• NCT number: NCT02493283
• Study type: Interventional
• Source: University Medicine Greifswald
• Status: Completed
• Phase: Phase 1
• Start date: September 2011
• Completion date: March 2015